Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14740279rdf:typepubmed:Citationlld:pubmed
pubmed-article:14740279lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C0337810lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C1533685lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C0021641lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C0184511lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C0376674lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C0040223lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C0086152lld:lifeskim
pubmed-article:14740279lifeskim:mentionsumls-concept:C0733228lld:lifeskim
pubmed-article:14740279pubmed:issue4lld:pubmed
pubmed-article:14740279pubmed:dateCreated2004-1-23lld:pubmed
pubmed-article:14740279pubmed:abstractTextWe investigated the use, in a short period, of Humalog Mix25 (Mix25) in a twice-daily administration regimen compared to a twice-daily injection therapy with Humulin 30/70 (30/70) in diabetic patients with Italian dietary habits. We studied 33 type 2 diabetic patients aged 59.1 +/- 8.1 years, BMI 29.8 +/- 2.7 kg/m2, duration of diabetes and insulin therapy of 14.4 +/- 9.8 and 4.2 +/- 4.6 years, respectively. After a 4-day lead-in period of twice-daily human insulin 30/70 treatment, patients were randomized to one of two treatment sequences: (1) a twice-daily regimen with Mix25 just 5 minutes before the morning and evening meals for 12 days, followed by a twice-daily therapy with human insulin 30/70 given 30 minutes before the morning and evening meals for an additional 12 days; or (2) the alternate sequence. Each patient underwent a mixed meal test: Humulin 30/70 was administered 30 minutes before the meal, while Mix25 was given 5 minutes before. The 2-hour post-prandial glucose concentration after breakfast was significantly lower during treatment with Mix25 than with Humulin 30/70 (157 +/- 43.2 vs. 180 +/- 43.2 mg/dl, p<0.05). The glycemic excursion after dinner on Mix25 treatment was significantly lower than with Humulin 30/70 (12.2 +/- 48.01 vs. 35.5 +/- 36.92 mg/dl, p<0.05). AUCglucose after Mix25 was lower than after Humulin 30/70. Glycemia after test meal was significantly lower with Mix25 than with Humulin 30/70. Insulin and free insulin concentrations after the test meal were significantly higher with Mix25 in comparison to Humulin 30/70. AUC serum insulin and free insulin curves after Mix25 were significantly higher than after Humulin 30/70 (p=0.028 and p=0.005, respectively). Twice-daily injections of Humalog Mix25, compared to human insulin 30/70 in type 2 diabetic patients with Italian dietary habits, provide improved and lasting post-prandial glycemic control, with the great convenience of the injection just before the meal.lld:pubmed
pubmed-article:14740279pubmed:languageenglld:pubmed
pubmed-article:14740279pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14740279pubmed:citationSubsetIMlld:pubmed
pubmed-article:14740279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14740279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14740279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14740279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14740279pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14740279pubmed:statusMEDLINElld:pubmed
pubmed-article:14740279pubmed:monthDeclld:pubmed
pubmed-article:14740279pubmed:issn0940-5429lld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:GalluzzoAAlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:ValleDDlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:CarleoRRlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:Di MarioUUlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:LunettaMMlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:CoscelliCClld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:CasalePPlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:CamporealeAAlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:IacobellisGGlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:GobboMMlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:CalderiniCClld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:LeonettiFFlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:PaleariFFlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:MeranteDDlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:PirroneVVlld:pubmed
pubmed-article:14740279pubmed:authorpubmed-author:FalcelliCClld:pubmed
pubmed-article:14740279pubmed:issnTypePrintlld:pubmed
pubmed-article:14740279pubmed:volume40lld:pubmed
pubmed-article:14740279pubmed:ownerNLMlld:pubmed
pubmed-article:14740279pubmed:authorsCompleteYlld:pubmed
pubmed-article:14740279pubmed:pagination187-92lld:pubmed
pubmed-article:14740279pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:meshHeadingpubmed-meshheading:14740279...lld:pubmed
pubmed-article:14740279pubmed:year2003lld:pubmed
pubmed-article:14740279pubmed:articleTitleImportance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits.lld:pubmed
pubmed-article:14740279pubmed:affiliationDepartment of Internal Medicine and Metabolic Diseases, Parma Hospital, Parma, Italy.lld:pubmed
pubmed-article:14740279pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14740279pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:14740279pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:14740279pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:14740279pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed